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Abstract 
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder associated with 
multiple cutaneous, physical and neurological symptoms. The aim of this study was to 
validate current NF1 severity scales using PCA, and relating the NF1 severity scale and 
components to cognitive and behavioural outcomes. Participants were 18 children diagnosed 
with NF1 aged 8 to 16 years. The PCA showed that NF1 symptoms could be divided into 
neurological and appearance symptoms. The presence of more neurological symptoms was 
associated with a lower score on the task Comprehension. More symptoms in the appearance 
were associated with less assertiveness. A higher total number of NF1 symptoms was 
negatively related to the scale meta-cognition of the BRIEF, indicating poorer executive 
functioning in daily life for children with more NF1 symptoms. Also, elevated autistic traits 
were observed using the SRS, and poorer emotion recognition as measured with the ANT. 
Together, these results might indicate that children with NF1 share a neuropsychological 
profile commonly seen in children with ASD, which might be related to neurological 
symptoms.   
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Neurological and Appearance-related symptoms in children with  
Neurofibromatosis type 1 (NF1):  
The relationship between NF1 severity and cognitive and behavioural outcomes 
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder and is one of the 
most common single gene disorders (Huson & Korf, 2007). NF1 was first described by Von 
Recklinghausen in the thirteenth century, which is why the disorder became known as Von 
Recklinghausen’s disease (Boyd, Korf, & Theos, 2009). The incidence of NF1 is 
approximately 1:3000 (Friedman, 1999; Moore & Denckla, 2000; North, 1998) to 1:3500 
(Levine, Materek, Abel, O’Donnell, & Cutting, 2006; Theos & Korf, 2006). NF1 is heritable, 
however, approximately 30 % to 50 % of the cases of NF1 result from spontaneous mutations 
(Levine et al., 2006). Severity and clinical expression of NF1 is variable, with different 
degrees of severity even within affected family members and generations (Easton, Ponder, 
Huson, & Ponder, 1993). 
 The NF1-gene is located on chromosome 17q11.2, and has the highest rate of new 
mutations of any known single-gene disorders (Theos & Korf, 2006). The NF1 gene encodes 
for neurofibromin, which serves as a tumour suppressor (Boyd, Korf, & Theos, 2009). 
Neurofibromin regulates the activity of the Ras protein, which regulates the signals for cell 
proliferation and differentiation (Theos & Korf, 2006). When the function of neurofibromin is 
impaired, regulation of cell proliferation and differentiation is disturbed, leading to 
uncontrolled cell proliferation (Boyd, Korf, & Theos, 2009). Known abnormalities associated 
with NF1 can be explained from an inability to regulate development of neural cells (Levine 
et al., 2006).  
The National Institutes of Health established the official diagnostic criteria for NF1 in 
their Consensus Development Conference Statement on Neurofibromatosis (1988). To 
diagnose NF1 two or more of the following criteria have to be met: 
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1. six or more café-au-lait macules over 5 mm in greatest diameter in pre-pubertal 
individuals and over 15 mm in greatest diameter in post-pubertal individuals. 
2. Two or more neurofibromas of any type or one plexiform neurofibroma. 
3. Freckling in the axillary or inguinal regions. 
4. Optic glioma. 
5. Two of more Lisch nodules (iris hamartomas). 
6. A distinctive osseous lesion such as sphenoid dysplasia or thinning of long bone 
cortex, with or without pseudo-arthrosis. 
7. A first-degree relative (parent, sibling, or offspring) with NF1 by the above criteria. 
Café-au-lait spots are present in over 99 % of the cases of NF1 and are often the first features 
to appear in children with NF1, developing between the ages of zero and two years (Huson & 
Korf, 2007). In the general population, the presence of café-au-lait spots is relatively normal 
(3 % - 36 %), however, the presence of multiple café au lait spots occurs only in less than 1 % 
of children and adults in the normal population (Landau & Krafchik, 1999). “Dermal” or 
“cutaneous” neurofibromas are benign tumours, arising from cell nerve sheaths (Theos & 
Korf, 2006), and these develop in almost all individuals with NF1 (>99 %) from the age of 
seven onwards, but mostly prepubertal (Huson & Korf, 2007). The number of neurofibromas 
that will develop is strongly variable and cannot be predicted. Plexiform neurofibromas, 
affecting multiple fascicles of a nerve and resulting in subcutaneous swellings, occur in 
approximately 30 % of the cases and can develop throughout childhood (Huson & Korf, 
2007). Freckling in the skinfolds is seen in 67 % of the children with NF1, developing from 
an age of three to five years old (Huson & Korf, 2007). Freckling often develops in the axilla 
and groin areas, but also in the neck and sub-mammary regions. A tumour of the optic nerve, 
an optic glioma, can be seen in approximately 15 % of the children with NF1 using imaging 
techniques. The optic glioma can increase in size, and can lead to decreased visual acuity and 
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destruction of continguous structures as a result of extension of the tumour (Listernick, 
Darling, Greenwald, Strauss, & Charrow, 1995). Also, a relationship between optic glioma 
involving the optic chiasm and precocious puberty has been found, which is hypothesized to 
be caused by the lesion affecting hypothalamus, resulting in interference with the 
hypothalamic-pituitairy-gonadal axis. (Habiby, Silverman, Listernick, & Charrow, 1995). 
Early puberty most often occurs after the age of six and can present with accelerated linear 
growth (Boyd, Korf, & Theos, 2009). Lisch nodules are small dome-shaped hyperpigmented 
macules of the iris (Boyd, Korf, & Theos, 2009). Of the individuals with NF1, 90 % to 95 % 
develops Lisch nodules (Huson & Korf, 2007). Abnormality of the development of the long 
bones, most commonly the tibia and fibula, as well as of the sphenoid bone, occurs in 
approximately 14 % of NF1 cases (DeBella, Szudek, & Friedman, 2000).  
 Despite not being part of the official diagnostic criteria, a number of other features 
have been related to NF1. These include macrocephaly (45 %), short stature (31,5 %), 
scoliosis (±9 %), and malignant tumours (1,5 %) (Huson & Korf, 2007). The cognitive and 
behavioural phenotype of NF1 can be described using the format of Hachon, Iannuzzi, and 
Chaix (2011). In their study they describe NF1 at the behavioural level, cognitive level, 
neurobiological level and genetic level.  
At the behavioural level, NF1 is characterized by learning disabilities, which are 
estimated to be present in 30-65 % of patients (Chabernaud et al., 2009; Hachon et al., 2011; 
Levine et al., 2006; North, 1998). The overall intelligence level is usually normal in 
individuals with NF1 (Hachon et al., 2011). In their review, Hachon et al. (2011) conclude 
from multiple studies that the IQ curve in the NF1 population shows a shift to the left, with 
the mean IQ of NF1 children being approximately 90, a significantly lower mean IQ than in 
the general population. Due to this shift of the IQ curve, a higher rate of mental retardation is 
found in children with NF1, since a larger percentage of the normal distribution for NF1, 
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approximately 6-7 %, will fall below the IQ value of 70, indicating mental retardation 
(Hyman, Shores, & North, 2005). There are no indications from recent studies for a 
significant difference between verbal en performal IQ (Hyman et al., 2005; Hyman, Shores, & 
North, 2006). Seeing the learning difficulties in the light of intelligence, Hyman and 
colleagues (2006) conclude that the group of children with NF1 with learning disabilities can 
be divided into children with general learning difficulties, having both a low general cognitive 
functioning and academic performance, and children with specific learning disabilities, with a 
higher general cognitive functioning but poor academic achievement. However, the cognitive 
profile of children with NF1 has distinct characteristics, which can remain unobserved in 
studies investigating full-scale IQ scores. According to Hyman and colleagues between 30 %-
50 % of individuals with NF1 meet the criteria for Attention Deficit Hyperactivity Disorder 
(ADHD) (Hyman et al., 2005; North, Hyman, & Barton, 2002). The majority of children with 
NF1 are diagnosed ADHD inattentive type, lacking the hyperactivity of the combined type 
(Noll et al., 2007). Huijbregts and De Sonneville (2011) have also found indications of a link 
between autism and NF1. In their sample, the largest difference between children with NF1 
and control children was found for autistic traits. Children with NF1 also have poorer social 
skills and more social problems than their healthy counterparts, as was found in multiple 
studies (Barton & North, 2004; Huijbregts & De Sonneville, 2011; Johnson, Saal, Lovell, & 
Schorry, 1999; Noll et al., 2007). More specifically, Noll et al. (2007) found that children 
with NF1 displayed less leadership behaviour, and were more sensitive and isolated, but were 
also more prosocial. Children with NF1 were selected less often as a friend by peers and had 
less reciprocated friendships. The presence of ADHD is a major risk factor for poor social 
outcomes and poor social skills (Barton & North, 2004). Children with NF1 also display more 
behavioural problems in other domains, such as conduct problems and emotional problems 
(Huijbregts & De Sonneville, 2011; Kayl & Moore III, 2000; Noll et al., 2007). 
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The behavioural phenotype of children with NF1 can be partly explained by the 
cognitive phenotype of children with NF1. Multiple attempts have been done to discern a 
comprehensive cognitive profile of children with NF1 (Hachon et al., 2011; Hyman et al., 
2005, 2006; Kayl & Moore III, 2000; Levine et al., 2006; North et al., 2002). Children with 
NF1 have been found to have an impairment of visuo-spatial skills (Clements-Stephens, 
Rimrodt, Gaur, & Cutting, 2008; Levine et al., 2006; Schrimsher, Billingsley, Slopis, & 
Moore III, 2003), language disabilities (Dilts et al., 1996; Hofman, Harris, Bryan, & Denckla, 
1994; Joy, Roberts, North, & De Silva, 1995), problems with fine motor coordination and 
motor speed (Hachon et al., 2011), and problems with executive functioning (Descheemaeker, 
Ghesquière, Symons, Fryns, & Legius, 2005; Ferner, 2007). More recently, Huijbregts and 
colleagues found evidence for a specific deficit in social information processing (Huijbregts, 
Jahja, De Sonneville, De Breij, & Swaab-Barneveld, 2009). Both the bottom-up encoding of 
social signals as well as the top-down appraisal of social signals was impaired in their group 
of children with NF1. Social information processing deficits in children with NF1 can explain 
conduct and peer problems (Huijbregts & De Sonneville, 2011). Recently, the theory has been 
proposed that the cognitive deficits in children with NF1 can be explained by cognitive 
control. Cognitive control, involving communication within and between brain areas, is 
hypothesized to be explanatory of the overall cognitive deficits of children with NF1 
(Rowbotham, Pit-ten Cate, Sonuga-Barke, & Huijbregts, 2009). This hypothesis has been 
confirmed in multiple studies, with children with NF1 showing a cognitive control deficit 
(Huijbregts & De Sonneville, 2011; Huijbregts, Swaab, & De Sonneville, 2010; Rowbotham 
et al., 2009). It seems that children with NF1 are able to catch up with respect to more basic 
cognitive abilities compared to the general population, but that deficits remain evident when 
they get older for tasks requiring more cognitive control (Huijbregts, Swaab, & De 
Sonneville, 2010). General cognitive ability, as defined by Huijbregts and De Sonneville 
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(2011) as a composite score of processing speed, social information processing, and cognitive 
control, can explain the emotional problems and social responsiveness of children with NF1. 
In this study, however, autistic traits remained evident, even after control for general 
cognitive ability. Also, Huijbregts et al. (2010) have found that cognitive control deficits can  
partly explain social information processing deficits. What can be concluded from these 
studies is that possibly, a more general deficit underlies the different cognitive profiles seen in 
children with NF1. This deficit can be further explained at a neurobiological level. 
As a result of the disturbed cell proliferation and differentiation, macrocephaly is 
present in approximately 45 % - 50 % of the cases (Huson & Korf, 2007; Steen et al., 2001). 
With the use of conventional MRI and MRI T1, a technique more sensitive to subtle structural 
changes in the brain, brain structures in NF-patients with macrocephaly can be mapped 
accurately.  Macrocephaly in NF1 patients is associated with enlargement of multiple midline 
brain structures and reduced white matter (Steen et al., 2001). Increases of grey and white 
matter have been found in multiple studies (Cutting et al., 2002; Greenwood et al., 2005; 
Moore III, Slopis, Jackson, De Winter, & Leeds, 2000; Steen et al., 2001). Steen et al. (2001) 
have found that increased white matter is also related to the presence of UBOs, Unidentified 
Bright Objects, which are bright areas on the MRI image indicating that these specific brain 
areas have different characteristics than the rest of the brain. DiPaolo and colleagues (1995) 
hypothesize that these areas consist of cerebral tissue with immature or edematous myelin 
sheaths, causing these areas to light up in MRI T2-weighted images due to excessive fluid. 
Studies investigating UBOs report on different numbers of NF1-patients presenting with 
UBOs, ranging from 43-79 % (Chabernaud et al., 2009), 64 % (Hyman et al., 2003), 60-70 % 
(Hyman, Gill, Shores, Steinberg, & North, 2007) and 50-74 % (Legius et al., 1995). UBOs 
have been investigated extensively in combination with cognitive outcomes, but with mixed 
results. It appears that UBOs in the thalamus are specifically related to cognitive deficits 
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(Chabernaud et al., 2009; Hyman et al., 2007). The brain abnormalities as described here are 
in support of the hypothesis by Rowbotham et al. (2009) about cognitive control. Cognitive 
control is based on functional connectivity, the idea that cognitive operations are performed 
by networks of brain regions, which are temporally correlated. A synchronous activation of 
the areas involved in the network is necessary for execution of cognitive operations 
(Rowbotham et al., 2009). As the thalamus is the part of the brain that coordinates the 
communication between brain regions (Rowbotham et al., 2009) and white matter and the 
grey-to-white matter ratio is involved in communication between brain areas, it is plausible 
that these abnormalities are related to impaired functional connectivity and cognitive control. 
This conclusion is also drawn by Hachon et al. (2011), who state that connectivity pathology 
between anterior and posterior cerebral areas is suggested by multiple studies.  
Disease severity 
As can be concluded from the literature discussed so far, there is major variability between 
individuals in the phenotype, endophenotype and genotype of NF1. Multiple researchers have 
tried to create a comprehensive scale to list the NF1 symptoms of individuals and the severity 
of these symptoms (Ablon, 1996; Huijbregts & De Sonneville, 2011; Noll et al., 2007; 
Riccardi, 1992; Sebold, Lovell, Hopkin, Noll, & Schorry, 2004). Severity scales include the 
presence of NF1 symptomatology, cosmetic difficulties, psychological problems, learning 
difficulties and ADHD status. These can be filled in by caretakers, although a possible lack of 
knowledge of caretakers, for example about medical issues, might create the need for 
additional information by a physician. Sebold and colleagues (2004), using an adaptation of 
the Riccardi scales as an objective measure of severity of the NF1 as rated by clinicians, but 
also a severity perception scale for parents and adolescents (Perception of Severity of Chronic 
Illness scale, PSCI), found that the severity as rated by parents and adolescents on the PSCI 
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was significantly correlated to the severity as indicated by the clinician. Severity was rated by 
the clinicians on four scales, cutaneous involvement, medical complications, cognitive 
impairment and behavioural problems. Severity perception of the parents was specifically 
correlated to medical, cognitive and behavioural problems of the child as rated by the 
clinician, for the adolescents themselves only cognitive severity perception, indicating 
cognitive problems such as learning difficulties as rated by the clinician, was significantly 
correlated to their severity perception, indicating that for adolescents cognitive impairments 
or learning problems contribute strongly to their perception of disease severity. 
However, although the present severity scales are informative, they are lacking in 
multiple areas. First, most severity scales lack a robust body of psychometric data (Noll et al., 
2007). Also, the present scales do not distinguish sufficiently between different features that 
might differ strongly regarding their impact. For example, cosmetic features, CNS 
abnormalities and physiological difficulties, but also cognitive impairments as was shown by 
Sebold and colleagues (2004), may have very different impacts, both qualitatively and 
regarding their impact on functioning and well-being. Present severity scales do not 
distinguish between symptoms and outcomes of NF1 either: for example, ADHD and learning 
disorders have been considered NF1-symptoms (Hyman et al., 2005; North et al., 2002; Noll 
et al., 2007) but may better be considered outcomes following NF1-specific pathology. 
Furthermore, despite the evidence for a link between NF1 and autism, no severity scale has 
yet incorporated autism at all. Also, none of the scales has introduced a weighting of the 
symptoms, while it seems plausible that some symptoms will have larger impact than others 
(e.g. malignant tumours versus café-au-lait spots). For research purposes, a better defined 
scale is necessary to adequately investigate the relationship between severity of NF1 and 
outcome measures. For clinical purposes, the introduction of a well-designed NF-1 severity 
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scale is necessary to assess the severity of the NF1 in patients. A severity index can give 
indications for further treatment, monitoring and support. In the Netherlands, the care system 
is based on the “need for support” of an individual. A good report on the severity of the NF1 
supports the quick and adequate offering of the required support. 
 Multiple studies have been performed investigating associations between the severity 
of NF1 and outcome measures. Huijbregts and De Sonneville (2011) found that disease 
severity, based on all domains except behavioural, psychological and learning problems, was 
not significantly related to social or behavioural outcomes. Noll et al. (2007) used three 
separate severity scales. The medical severity scale was only significantly related to attention 
as reported by fathers. The physical scale was not significantly related to any of the outcome 
measures, whereas the neurological scale was significantly related to multiple measures of 
social, emotional and behavioural functioning (peer problems, internalizing and externalizing 
problems, attention problems, depression and conduct problems). However, as stated 
previously, this severity scale included outcome features like ADHD and learning problems, 
so an association with peer problems and attention problems seems obvious. It seems 
plausible that the results have been confounded, and that no clear statements can be made 
about the relationship between neurological severity and social and behavioural outcomes 
without a better defined severity scale.  
Current study 
In this study, a new NF1 severity scale will be introduced, based on the strengths and 
limitations of existing scales. The scale will be a questionnaire for parents, but with room to 
contact the patients’ physician for supplementary information. A weighting of symptoms will 
be included in the scoring system in order to give a more precise representation of the severity 
of the NF1 in the patients. A first aim of this study is to validate existing NF1-severity scales 
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using statistical techniques. Existing NF1 severity scales are based on theory, for example the 
medical, physical, and neurological severity scales (Noll et al., 2007) or the cutaneous, 
medical, cognitive and behavioural severity scales (Sebold et al., 2004). By investigating the 
factor structure of the present severity scale, statistical evidence will be given for the division 
of NF1 severity scales in separate factors. It is hypothesized that a two-factor structure will be 
found, dividing the symptoms of NF1 into neurological symptoms and cosmetical, physical or 
cutaneous symptoms like café-au-lait spots or itching. Behavioural problems as investigated 
with the NF1 severity scale, e.g. ADHD, peer- and social problems etc., are assumed to be a 
result of cognitive deficits, based on previous results by Huijbregts and De Sonneville (2011), 
and are not hypothesized to be a separate factor. Since cognitive deficits are related to 
abnormalities on brain-level (Rowbotham et al., 2009), it is hypothesized that behavioural 
problems as a result of cognitive deficits will be related to the neurological factor of the NF1 
severity scale. However, social- and peer problems may also be caused by cosmetical and 
physical symptoms, for example due to bullying or exclusion by peers. 
A second aim of this study is to relate the NF1 severity factors to cognitive, social, and 
behavioural outcome measures. Social and behavioural outcomes will be assessed using 
questionnaires, whereas cognitive functioning will be assessed using clinical testing. Based on 
the literature on cognitive impairments in children with NF1 (Hachon et al., 2011; Huijbregts 
& De Sonneville, 2011; Huijbregts et al., 2010; Rowbotham et al., 2009; Huijbregts, et al. 
2009), assessments included intelligence, cognitive control and social information processing. 
Sustained attention was measured in order to assess possible attention deficits, as executive 
functioning problems have been previously found in children with NF1 (Descheemaeker, 
Ghesquière, Symons, Fryns, & Legius, 2005; Ferner et al., 2007). Although there are some 
indications for a relationship between severity of NF1 and social and behavioural outcomes, 
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no specific relationships have been found. However, most studies report that a possible reason 
for the lack of a relationship between severity and outcome measures is the severity scale that 
is used. Therefore, it is hypothesized that the total severity as indicated by the present NF1 
severity scale, including weighting of the symptoms, will be related to cognitive, social and 
behavioural outcomes. Also, it is hypothesized that the severity factors, excluding outcomes 
as measured by the NF1 severity scale in order to avoid bias, will be specifically related to 
certain outcome variables. As with the outcomes measured by the NF1 severity scale, it is 
hypothesized that the cognitive and behavioural outcomes will be most strongly related to the 
neurological factor. By creating a more valid scale of severity, the relationship between 
severity and social and behavioural outcomes can be studied more thoroughly.  
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Method 
Participants 
Participants of the study were 18 Dutch children and adolescents diagnosed with 
Neurofibromatosis Type 1 (NF1) (11 boys, 7 girls, mean age 12;8 years, SD 2;4 years, range 
8;2-16;7). All participants fulfilled the diagnostic criteria for NF1 specified by the National 
Institutes of Health Consensus Conference (1988). The participants were recruited through the 
Dutch Neurofibromatosis Association by means of advertisements in the newsletter and on 
their website, as well as through a written letter informing eligible participants of the study. 
Participating families lived in various areas of Holland including rural and urban areas in 
different regions. Written informed consent was obtained from parents and participants, with 
parents confirming willingness to participate for children under the age of 18. Ethical 
approval for the study was granted by Leiden University’s education and Child Studies Ethics 
Committee.  
 
Instruments 
Disease severity 
Disease severity was measured with a parent questionnaire which was constructed by the 
research group. The questionnaire was based on existing severity scales by Ablon (1996), 
Huijbregts and De Sonneville (2011), Noll et al. (2007), and Riccardi (1992). All known 
symptoms and outcomes of NF1 were included, such as café-au-lait spots, neurofibromas, 
macrocephaly, malignant tumours, learning problems, ADHD and Autism Spectrum 
Disorders (ASD) (for the full questionnaire see appendix a). All symptoms are listed in Table 
2. A question involving disease severity perception (“Does your child experience his/her 
symptoms as a burden?”) was also added. Questions were constructed hierarchically, parents 
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first answered whether a symptom was present, and if so, in what amount it was present, e.g. 
“Does your child have café-au-lait spots? If yes, could you indicate how many?”. ADHD and 
ASD status were asked as diagnosed by a clinician and included medication status, but was 
also asked in the opinion of the rater (e.g. “In your opinion, does your child display ADHD 
characteristics?”). Scoring of the symptoms was done by scoring non-presence of a symptom 
as 1 and presence of the symptom as a 2. A weighting of the symptoms was included for the 
variables café-au-lait spots, neurofibromas, spinal anomalies, benign tumour, and itch (table 
1). The weighting of the symptoms was done by studying the nature of the symptoms. As this 
NF1 severity scale was newly constructed by the research group, no information can be 
provided about the reliability or factor structure of the disease severity scale.  
 
Table 1. Weighted variables. 
Variables  Weighting  
Café-au-lait spots 1 = 1-29 café-au-lait spots 
2 = ≥ 30 café-au-lait spots 
Neurofibromas 1 = no neurofibromas 
2 = 1-9 neurofibromas 
3 = ≥ 10 neurofibromas 
Plexiform neurofibromas = +1 
Spinal Anomalies 1 = no spinal anomalies 
2 = spinal anomalies present 
3 = spinal anomalies present and under treatment 
Benign tumour 1 = no tumour 
2 = benign tumour present 
3 = benign tumour present and under treatment 
Itch 1 = no itch 
2 = itch present 
3 = itch present and treated with medication 
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Cognitive functioning 
 WISC-IIInl. 
Intelligence of the children and adolescents with NF1 was estimated using multiple subtests 
from the Dutch translation of the Wechsler Intelligence Scale for Children, third edition 
(WISC-IIInl; Wechsler, 2002). The WISC-IIInl has been rated sufficient to good by the Dutch 
test committee (COTAN), with exception of the criteriumvalidity which was rated 
insufficient. The subtests used were Picture Completion, which measures the ability to 
observe part-whole relationships, Coding version B, measuring processing speed, Block 
Design, which measures the ability to observe part-whole relationships and construction 
abilities, Vocabulary, measuring Word knowledge and verbal fluency, Comprehension, 
measuring general knowledge and verbal fluency in social situations, and Symbol Search 
version B, measuring processing speed. Administration and scoring was done in line with the 
official test manual. Raw scores were transformed into standard scores using age-appropriate 
norms, with a Mean of 10, SD 3. A higher score indicated a higher better performance on the 
subtest, giving an indication for a higher total IQ. 
 ANT. 
Three tasks of the Amsterdam Neurological Tasks (ANT; De Sonneville, 1999) were used to 
assess social information processing, sustained attention and cognitive control respectively. 
De ANT is a computerized battery for neuropsychological testing of children. Test–retest 
reliability and construct-, criterion-, and discriminant validity of the ANT are satisfactory, as 
described by Rowbotham and colleagues (2009).  Test administration was done according to 
the test manual, involving standardized verbal instruction supported by a visual example of 
the test, a practice session and the test administration.  The tasks will be described in more 
detail below. 
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  Identification of facial emotions. 
The task Identification of facial emotions (IFE) examined the ability to recognize emotions 
from facial expressions. The task consisted of eight parts, each with another target variable. 
The participants matched faces on a digitalized photograph with the target variable of the 
specific part by clicking on the ‘yes’ or ‘no’ button on the mouse. The target emotions of the 
eight conditions were respectively happy, sad, angry, fear, surprise, disgust, shame, and 
contempt. Each trial consisted of 20 trials of the target emotion and 20 trials of a random 
selection of other emotions, 40 trials in total. Better social information processing was 
indicated by more accurate answering, as indicated by less incorrect answers, calculated by 
adding the misses en false alarms of each trial.  
  Sustained attention dots. 
The task Sustained attention dots (SAD) assessed sustained attention. On the screen, 
participants would see a square with three, four or five dots. Four dots were the target 
stimulus for which children had to press the ‘yes’ button on the mouse, when three of five 
dots appeared the ‘no’ button had to be pressed. After pushing the button the next stimulus 
would appear. The test consisted of 600 trials, duration of the task depended on reaction time 
of the respondent but ranges overall between 15 and 30 minutes. Inhibition of an inaccurate 
response was calculated by subtracting the mean of the false alarms for low and high dots 
from the misses of all trials. The result of this calculation, called Bias, is a clean measure of 
inhibition, since it only measures impulsive inaccurate responses. A combined measure of 
inhibition and sustained attention was calculated by computing the difference between the 
Bias measure of the first 120 trials (block 1) and the last 120 trials (Block 5). Better sustained 
attention was indicated by a lower Bias score for the total test and for the difference between 
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the first and the fifth block, since this indicated less impulsive errors and a smaller increase of 
impulsive errors over time. 
  Memory search two-dimensional objects. 
The task Memory search two-dimensional objects (MS2D) examined working memory. The 
participant had to remember and detect a target object defined by colour and form (e.g. a red 
circle) from a subset of four objects. In the first condition the participant had to remember one 
target object, a red circle, and detect it in 48 trials. In the second condition (48 trials), the 
participant had to remember and detect three objects, a blue triangle, a green square and a 
yellow cross. When one of the target stimuli was present in the subset of four objects, the 
participant had to press the ‘yes’ button, when none of the target stimuli was present the 
participant pressed the ‘no’ button. Because of the test construction, cognitive control could 
be increased in a controlled manner by increasing working memory load and task demands. A 
better cognitive control is indicated by a smaller increase in the amount of errors in the second 
task compared to the first task. This was calculated by subtracting the number of misses and 
false alarms in the first task from the number of misses and false alarms in the second task.  
Social Functioning 
 SSRS. 
The Social Skills Rating System (SSRS; Gresham & Elliot, 1990) was used to assess social 
behaviour. The SSRS assesses two domains, social skills and problem behaviour. Only the 
domain social skills was used and completed by the parents. The parent form consists of four 
scales. The Cooperation subscale consists of behaviours such as helping and sharing (e.g. 
“offers out of his/her own accord to help with tasks”). The Assertion subscale includes 
initiating behaviours (e.g. “takes part in group activities out of his/her own accord”). The 
Responsibility subscale consists of items regarding communication with adults and regard for 
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property or work (e.g. “Discusses unreasonable house rules in an appropriate manner”) and 
the Self-control subscale consists of behaviours that include self-control in conflict and non-
conflict situations (e.g. “Handles criticism in an acceptable manner”). The questionnaire 
consisted of 38 items, to be rated on a three-point likert scale (1= Never; 2= Sometimes; 3= 
Very often). A higher total score on the SSRS indicated better social skills in children. The 
score on the scale can be compared to mean scores of the norm group. Parents completed the 
SSRS in approximately 10 minutes. Reliability and validity of the SSRS were satisfactory 
(Diperna & Volpe, 2005).  
Behavioural Functioning 
 SRS. 
The Social Responsiveness Scale (SRS; Constantino, 2002) was used to examine autistic 
traits. The SRS is designed to assess autistic traits, using five scales based on known 
impairments in children with an ASD. The first scale measures ‘receptive’ social impairments 
and includes items on awareness of social information (e.g. “is aware of feelings and thoughts 
of others”). The ‘cognition’ scale represents social information processing (e.g. “gets upset in 
situations in which a lot is going on”). The ‘expressive’ scale represents the capacity for 
reciprocal social communication (e.g. “is awkward in taking turns in interaction with peers”). 
The ‘motivation’ scale assesses social anxiety or avoidance (e.g. “Would rather be alone than 
with others”). The fifth scale is the scale Autistic Preoccupations (e.g. “Has an unusually 
limited area of interest”). The total of all scales gives an indication for the severity of autistic 
spectrum symptoms. A higher total score indicated more severe autistic spectrum symptoms. 
The SRS was completed by the parents in approximately 15 minutes. It consisted of 65 items 
rated on a four-point likert scale (1= never true; 2= sometimes true; 3= often true; 4= almost 
always true). The score on the scale can be interpreted using the interpretation in the manual 
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of the SRS based on T-scores. Reliability and validity of the SRS are acceptable; an extensive 
overview of literature on the psychometric properties of the SRS is given by Bölte, Poustka & 
Constantino (2008).  
DEX-K. 
The Dysexecutive Questionnaire (DEX; Wilson, Aldermann, Burgess, Emslie, & Evans, 
1996) is part of the Behavioral Assessment of the Dysexecutive Syndrome (BADS). The 
questionnaire measures problems in daily functioning as a result of planning and organisation 
problems. The DEX-K, the Dutch version of the DEX for children, consists of 20 items, the 
total score is the sum of the items. Items are rated by parents on a four-point scale (0= Never, 
1= Occasionally, 2= Sometimes, 3= Often, 4= Very often). A higher score on the DEX-K 
indicated greater executive functioning problems. The score on the scale can be compared to 
mean scores of the norm group. Reliability and validity are considered acceptable 
(Chamberlain, 2003). 
 BRIEF. 
The Behavior Rating Inventory of Executive Function (BRIEF; Gioia, Isquith, Guy, & 
Kenworthy, 2000) is a questionnaire assessing executive functioning in home and school 
environments. The BRIEF consisted of 75 items on eight clinical scales; Inhibition (e.g. 
“blurts out things impulsively”), Cognitive Flexibility (e.g. “gets upset in new situations”), 
Emotion Regulation (e.g. “reacts exaggerated to small problems”), Initiating (e.g., “doesn’t 
start on his/her own), Working Memory (e.g. “has trouble remembering things, even for a 
couple of minutes”), Planning and Organizing (e.g. “underestimates time needed to get tasks 
finished”), Orderliness and Neatness (e.g. “leaves playing area messy”), and Behaviour 
Evaluation (e.g. “doesn’t know his/her own strengths and weaknesses”). The scales form two 
indexes, Behavioural regulation (Inhibition, Cognitive Flexibility and Emotion Regulation) 
Neurological and Appearance-related symptoms in children with Neurofibromatosis type 1 (NF1): The relationship between 
NF1 severity and cognitive and behavioural outcomes 
  24 
and Metacognition (Initiating, Working Memory, Planning and Organizing, Orderliness and 
neatness, and Behaviour Evaluation). The global executive composite score is the total of all 
items. Parents answer the items on a three-point likert scale (1= Never; 2= Sometimes; 3= 
Often). A higher score on the indexes and total score indicates more executive functioning 
problems. Reliability and validity are acceptable according to the authors (Gioia et al., 2000).  
 CBCL. 
The Child Behavior Checklist 6-18 (CBCL; Achenbach & Rescorla, 2001) is a parent 
questionnaire assessing behaviour- and emotional problems and skills in children 6-18 years 
old. The CBCL consists of 113 items to be rated on a three-point likert scale (0= not at 
all/never; 1= a little/sometimes; 2= clearly/often). The items are divided over 9 syndrome 
scales: Anxious/Depressed, Withdrawn/Depressed, Somatic Complaints (Internalizing scale), 
Rule-breaking Behaviour, Aggressive Behaviour (Externalizing scale), Social Problems, 
Thought Problems, Attention Problems, and other. All items on behaviour together form the 
Total Problems scale. The items can also be divided over 6 DSM-oriented scales: Affective 
Problems, Anxiety Problems, Somatic Problems, Attention Deficit/Hyperactivity Problems, 
Oppositional Defiant Problems, and Conduct Problems. A higher score on a scale indicates 
more problem behaviour on the domain of the scale. Scores can be compared to norm scores 
for peers. 
Procedure 
The current study is part of a larger study of NF1 patients and controls on brain functioning in 
relationship to cognitive and behavioural outcomes by Leiden University. Participants could 
contact the project leader via e-mail or phone after reading the recruitment advertisement. 
Supplemental information was then sent by mail, informing the participants more fully about 
the study and including an informed consent form. If respondents were willing to participate 
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they were contacted via phone or during the MRI assessment for a home visit, during which 
the questionnaires were handed to the parents. During the home visit, all cognitive measures 
were administered with the child in a quiet room. Parents handed back the questionnaires 
during the home visits. After completion of the study, participating families received a report 
on the outcomes of the study.  
Data-analysis 
First, the data were inspected to study the properties of the variables and to check for missings 
and outliers. Correlations were calculated for the variables of the NF1 severity list to check 
whether an underlying factor structure might be present. To investigate the factor structure of 
the NF1 severity scale, a Categorical Principal Component Analysis (CATPCA) was 
executed. This technique allowed for investigation of principal components in the structure of 
the NF1 severity scale, including categorical and numeric variables, without an a priori 
theory. A CATPCA was performed using the variables representing severity of the symptoms 
in the participants. Behavioural outcomes of the NF1 (speech problems, gross and fine motor 
problems, learning impairments, ADHD, ASD, psychological problems and social problems), 
severity perception (whether the NF1 is a burden) and the question whether the NF1 is 
familial, were left out of the CATPCA in order to get a valid component structure of the 
objective symptoms involved in severity of NF1. Dichotomous variables, e.g. variables with a 
yes- or no answer, for example “Does your child have freckling in the groin area, yes or no?”, 
were considered nominal. Weighted variables were considered numeric. Inspecting the 
loading plots showed no abnormalities in the quantifications of the variables, indicating that 
the measurement levels had been set appropriately. The weighted scores were quantified in an 
ascending manner, with equal distances, indicating that a score of three was indeed higher on 
the severity scale than a score of two or one.  
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With use of the CATPCA, quantifications of the variables were computed. The 
quantifications of the variables were then used to perform a Principal Component Analysis 
(PCA), which allows for rotation of the components. With the use of orthogonal rotation, the 
component structure was analyzed for subscales. To assess a possible influence of certain 
variables on the component structure, biplots were made to visually investigate the 
relationship between these variables and the component structure. The components have next 
been saved per participant and the Pearson correlation was calculated between the component 
scores and scores on the behavioural and cognitive outcome measures. 
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Results 
In Table 2 the symptoms of NF1 as investigated by the NF1 severity scale have been listed, 
including the percentage of participants presenting with these symptoms. Of the 18 
participants, all presented with café-au-lait spots. Malignant tumours, epilepsy, hormonal 
problems and conduct problems were not present in any of the participants en will therefore 
be eliminated from further analyses. One child presented with hypertension, however, this 
was the result of medication, and could not be considered a symptom of NF1, therefore, 
hypertension will also not be used in further analyses.  
 
Table 2. Percentage of participants with NF1 presenting with symptoms. 
Symptoms % with symptoms 
 
Symptoms %  with symptoms 
Café-au-lait spots 100%  Spinal anomalies 50% 
Neurofibromas 66,7%  Hypertension 5,6% 
Plexiform Neurofibromas 27,8%  Hormonal problems 0% 
Skinfold Freckling axilla 83,3%  Headache 50% 
Skinfold Freckling Groin 77,8%  Itch 16,7% 
Optic Glioma 11,1%  Gross motor skills 77,8% 
Lisch Nodules 55,6%  Fine motor skills 66,7% 
Osseous Lesions 11,1%  Speech Problems 61,1% 
First-degree relative with NF1 33,3%  ADHD 33,3% 
UBOs 27,8%  ASD 11,1% 
Benign tumour 22,3%  Learning Problems 66,7% 
Malignant tumour 0%  Social Problems 55,6% 
Macrocephaly 55,6%  Conduct Problems 0% 
Epilepsy 0%  Psychological Problems 5,6% 
 
Neurological and Appearance-related symptoms in children with Neurofibromatosis type 1 (NF1): The relationship between 
NF1 severity and cognitive and behavioural outcomes 
  28 
In table 3, the mean total severity score and the mean total severity score with weighting are 
presented, as well as the mean scores on all outcome measures. If the performance can be 
described in a classification, indicating the performance compared to peers as described in the 
test manual, the classification of the mean score is added. The mean score on the severity and 
the weighted severity scale is comparable. The mean scores on the WISC-IIInl are average, 
except for the performance on Block Design, which is weak, children with NF1 perform 
weaker than the norm group of the WISC-IIInl indicating poorer visual-spatial skills. On IFE, 
the children with NF1 gave most incorrect answers in the sad condition. Children with NF1 
appear to have a variable performance on a task assessing social information processing, 
depending on the type of information that has to be processed. The Bias score of the task SAD 
is positive, indicating that the participants made more inhibitory errors relative to other errors. 
The SAD Bias measure over time, incorporating sustained attention is negative, indicating 
that the participants made less impulsive errors over time, indicating no significant sustained 
attention problems. The mean score on the cognitive control measure, MS2D, is positive, 
indicating that children with NF1 made more errors when cognitive control was increased. 
The mean score on the DEX-K is average compared to the mean score of the norm group 
(Wilson, Aldermann, Burgess, Emslie, & Evans, 1996). The mean score of the NF1 children 
on the SRS is higher than average when compared to peers. The mean score (M=65,47), 
corresponds to a T-score of 60-75, indicating “deficiencies in reciprocal social behaviour that 
are significant, and are resulting in mild to moderate interference in everyday social 
interactions” (Constantino, 2002). The NF1 participants display more autistic traits than their 
peers without NF1. The mean on the SSRS of the NF1 children is above average, the mean 
score corresponds to a standard score of 84-94 depending on age and gender (Gresham, & 
Elliott, 1990). The participants display above average social skills compared to peers without 
NF1. Due to limited availability of the profile scores of the CBCL, scores on the CBCL scales 
Neurological and Appearance-related symptoms in children with Neurofibromatosis type 1 (NF1): The relationship between 
NF1 severity and cognitive and behavioural outcomes 
  29 
are compared to the profile score of boys 6-18 years of age (Achenbach, 2001), but not for 
girls. The mean score on the Withdrawn/Depressed score of the NF1 children is in the 
borderline clinical range for boys 6-11. For older boys, this score is normal. The score on the 
Social Problems scale is in the borderline clinical range, indicative of elevated social 
problems. On the Internalizing scale, the NF1 children score in the borderline to clinical 
range, indicating elevated internalizing problems compared to boys without NF1. Overall, the 
participants display more behaviour problems than boys without NF1, indicated by a Total 
score in the borderline to clinical range. 
Correlation NF1 severity scale 
The correlation analysis of the data has shown some significant correlations within the NF1 
severity scale (-0,64<r<0,85). The fact that only a few significant correlations were found can 
be explained by the low number of participants and small variations between scores. The 
correlation matrix gives an indication that the sub domains are related and that an underlying 
factor structure might be present. 
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Table 3. Mean scores on NF1 severity scale and outcome measures including classification. 
Instrument  Mean SD Classification  Instrument Mean SD Classification 
NF1 severity scale total 19,28 1,67 -   BRIEF total 142,94 34,28 - 
NF1 severity scale weighted total 19,56 2,33 -  SRS Total 65,47 25,65 Mild to moderate deficienciesc 
WISC Picture Completion 9,29 3,04 Averagea  SSRS Total 46,65 14,94 Above averaged 
WISC Block Design 7,18 3,26 Weaka  CBCL Anxious Depressed 4,56 3,33 Normale 
WISC Vocabulary  9,12 3,03 Averagea  CBCL Withdrawn Depressed 4,44 3,20 Normal-borderlinee 
WISC Comprehension  8,35 2,74 Averagea  CBCL Somatic Complaints 3,83 2,18 Normale 
WISC Symbol Search  8,88 3,08 Averagea  CBCL Social Problems 8,00 4,64 Borderlinee 
WISC Coding  9,82 2,40 Averagea  CBCL Thought Problems 4,61 4,16 Normale 
IFE happy errors 1,18 1,24 -   CBCL Attention Problems 8,56 4,80 Normale 
IFE sad errors 9,53 6,77 -  CBCL Rule-breaking Behaviour 2,94 1,95 Normale 
IFE angry errors 4,53 2,65 -  CBCL aggressive Behaviour 7,78 6,24 Normale 
IFE fear errors 4,82 4,50 -  CBCL Other 5,00 2,93 - 
IFE disgust errors 4,47 3,61 -  CBCL Internalizing Problems 12,83 7,06 Borderline-clinicale 
IFE surprise errors 4,59 2,55 -  CBCL Externalizing Problems 10,72 7,35 Normale 
IFE shame errors 6,00 4,65 -  CBCL Total Problems 49,72 26,06 Borderline-clinicale 
Neurological and Appearance-related symptoms in children with Neurofibromatosis type 1 (NF1): The relationship between NF1 severity and cognitive and behavioural outcomes 
  31 
IFE contempt errors 6,24 5,25 -  CBCL Affective Problems 5,50 3,00  
SAD Bias 9,82 10,88 -  CBCL Anxiety Problems 3,00 1,88  
SAD Bias/SA -1,59 2,54 -  CBCL  Somatic Problems 2,06 1,30  
MS2D cognitive control 15,29 6,73 -  CBCL Attention Deficit/Hyperactivity Problems 6,28 3,89  
DEX-K total 28,24 16,62 Averageb  CBCL Oppositional Defiant Problems 3,22 2,34  
BRIEF Behaviour regulation index 51,94 16,48 -  CBCL Conduct Problems 3,11 2,56  
BRIEF Metacognition index 92,59 19,99 -    
aClassification based on M=10 (SD=3) (Wechsler, 2002) 
bClassification based on M=15,7 (SD=13,6) (Wilson, Aldermann, Burgess, Emslie, & Evans, 1996) 
cClassification based on M=30,5 (SD=19,7), mean score refers to T-score 60-75 (Constantino, 2002). 
dClassification based on Standard Score 84-94 depending on age and gender (Gresham, & Elliott, 1990). 
eClassification based on scoring profile for boys 6-18 years (Achenbach, 2001).
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Principal Component Analysis 
An exploratory CATPCA was performed, without a fixed set of components. After 
exploration of component loadings, a two or three-component solution was considered most 
suitable for the data. A CATPCA including three components was executed, this model 
accounted for 60 % of the variance in the data, which is acceptable, indicating that more than 
half of the variance in the data is accounted for by the three components. However, when 
examining the component solution, no meaningful interpretation could be given for the three 
components. A two-factor solution explained 44 % of the variance in the data, with the first 
component explaining 24 %, indicating that all severity measures load on a common factor, 
and the second component explaining 20 % of the variance. Inspection of the component 
loadings resulted in a clear segmentation of the data on two dimensions, as presented in figure 
1. The symptoms freckling in the axilla and groin area, café-au-lait spots, itch and osseous 
lesions all load highly on the first dimension. Spinal anomalies and lisch nodules load 
negatively on the first dimension. The symptoms optic glioma, benign tumour, headache and 
UBO load highly on the second dimension, macrocephaly loads negatively on the second 
dimension. 
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Figure 1. loading plot of NF1 severity scale. 
 
To increase the interpretability of the component solution, the symptom quantifications were 
inserted in a PCA two-factor solution with orthogonal (varimax) rotation. Inspection of the 
correlation between the factors using oblique rotation showed that the components were not 
correlated (r = 0.001). Therefore an orthogonal rotation was done, eliminating influence of 
component correlations. The component loadings have been listed in table 4, the loadings of 
the separate components have been outlined. 
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Table 4. Component loadings of NF1 severity symptoms on two components. 
 Component 
 1 2 
Skinfold Freckling Axilla ,86 ,34 
Skinfold Freckling Groin ,78 ,25 
Lisch Nodules -,70 ,06 
Spinal Anomalies -,58 ,15 
Itch ,47 -,07 
Café-au-lait spots ,47 ,35 
Osseous Lesions ,35 -,13 
Benign Tumour -,35 ,83 
Headache ,01 ,77 
Optic Glioma -,48 ,68 
Macrocephaly -,13 -,53 
UBOs -,05 ,43 
Neurofibromas ,17 ,31 
 
The symptoms skinfold freckling in the axilla and groin area, itch, café-au-lait spots and 
osseous lesions load highly on the first component, lisch nodules and spinal anomalies load 
negatively on the first component, indicating that children who score high on symptoms like 
skinfold freckling and café-au-lait spots usually score low on lisch nodules and spinal 
anomalies. The symptoms benign tumour, headache, optic glioma, and UBOs load highly on 
the second component, macrocephaly loads negatively on the second component. 
Neurofibromas load highest on the second component, however, the loading is lower than 
0.35, indicating that neurofibromas do not add significantly to either component. Investigating 
the symptoms involved in each component, the first component represents symptoms which 
involve appearance and are visible for others. Since lisch nodules and spinal anomalies are 
often not visible for the naked eye, these load negatively on this component. The second 
component represents neurological symptoms. However, although macrocephaly also 
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involves the brain, this symptom does not fit the present component structure. When 
inspecting the biplot labelling the participants by macrocephaly (figure 2), it is shown that 
participants with macrocephaly seem to represent a unique group within the present sample, 
related to almost none of the other variables. Excluding macrocephaly from the component 
structure however, would expel this symptom from NF1 severity, which cannot be justified 
based on the data since more than half of the participants presented with macrocephaly. The 
component structure as was established with the PCA seems the most suitable component 
structure for the data.  
Figure 2. Biplot of component structure including participants labelled by macrocephaly 
(1=no macrocephaly; 2=macrocephaly). 
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To investigate the hypothesis whether behavioural severity measures as measured with the 
NF1 severity scale (speech problems, gross and fine motor problems, learning impairments, 
ADHD, ASD, psychological problems and social problems), severity perception (whether the 
NF1 is a burden) and familial NF1 were related to one of the factors, these variables were 
inserted in the component structure. The component loadings are shown in table 5. Due to the 
influence of the added variables, some shifts have occurred in the component structure. Spinal 
anomalies correlates positively with the neurological symptoms optic glioma, UBO, benign 
tumour and headache. Osseous lesions are negatively related to the neurological component. 
The second component remains related to visible symptoms, e.g. café-au-lait spots, skinfold 
freckling in the axilla and groin area and itch. Lisch nodules load negatively on the second 
component. Component loadings <0.35 are not considered in the component structure, since 
these variables contribute only marginally to the component structure and cannot be 
considered meaningful. 
Whether the NF1 is familial or not seems to be related to visible symptoms, indicating 
that people with more NF1 symptoms in their appearance more often have familial NF1. 
Disease perception, whether the child experiences the NF1 as a burden or not, is most strongly 
related to symptoms involving the neurological component. The behavioural outcome ADHD 
is related to the neurological component, children with more neurological symptoms have 
ADHD more often. Fine motor impairments are negatively related to the neurological 
component, indicating that fine motor problems occur less when there is more neurological 
involvement. Speech problems are negatively related to visible symptoms, whereas ASD is 
positively related to visible symptoms. Children who have more visible symptoms have less 
speech problems, but more often a diagnosis of ASD.  Social problems are not significantly 
related to either of the components.  
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Table 5. Component loadings of NF1 severity symptoms including perception, external and 
behavioural symptoms on two components. 
 Component 
 1 2 
Optic Glioma 0,85 0,12 
Benign tumour 0,84 0,21 
ADHD 0,63 0,13 
Fine motor skills -0,56 -0,02 
UBOs 0,47 -0,02 
Headache 0,45 0,29 
Spinal anomalies 0,43 -0,33 
Osseous Lesions -0,41 -0,10 
Burden 0,38 -0,18 
Learning problems 0,33 -0,15 
Gross motor skills -0,27 0,11 
Psychological problems -0,23 0,15 
Skinfold Freckling Groin -0,32 0,70 
Café-au-lait spots 0,00 0,68 
Speech problems -0,19 -0,64 
Skinfold Freckling Axilla -0,36 0,54 
ASD -0,14 0,53 
Family member 0,34 0,51 
Itch -0,27 0,49 
Lisch Nodules 0,44 -0,45 
Neurofibromas 0,15 0,33 
Macrocephaly -0,26 -0,30 
Social problems -0,03 -0,28 
 
 
Relationship between components and outcome measures  
The relationship between disease severity and behavioural outcomes has been explored by 
inserting behavioural symptoms in the component structure of the severity scale To get a 
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more thorough picture of the relationship between the component structure of the NF1 
severity scale and behavioural outcomes, correlations have been computed between the scores 
of the participants on the components and cognitive and behavioural outcome measures. The 
component structure as calculated excluding the behavioural outcomes, disease perception 
and familial NF1, has been used to assess the correlations, in order to avoid bias. The 
correlations between the component scores and total scale score and the scores on the 
outcome measures are represented in table 6. 
 
 
Table 6. Correlations between components scores and outcome measures. 
 
Appearance 
Component Sign. 
Neurological 
Component Sign. 
Total scale 
score 
Sign. 
WISC Picture Completion  .30  N.S. -.07  N.S. .03  N.S. 
WISC Block Design   .18 N.S. -.31  N.S. -.15  N.S. 
WISC Vocabulary   .19  N.S. -.27  N.S. -.24  N.S. 
WISC Comprehension   .36  N.S. -.44  .08* -.14  N.S. 
WISC Symbol Search   -.14  N.S. .56  .02** .64  .01** 
WISC Coding  .04  N.S. .17  N.S. .13  N.S. 
ANT IFE happy errors  -.19 N.S. .10 N.S. -.08 N.S. 
ANT IFE sad errors  -.52 .03** .14 N.S. -.11 N.S. 
ANT IFE angry errors  -.21 N.S. .25 N.S. .15 N.S. 
ANT IFE fear errors  -.31 N.S. .20 N.S. .04 N.S. 
ANT IFE disgust errors  .26 N.S. .05 N.S. -.26 N.S. 
ANT IFE surprise errors  .13 N.S. -.17 N.S. -.48 .05** 
ANT IFE shame errors  .26 N.S. -.27 N.S. -.61 .01** 
ANT IFE contempt errors  -.01 N.S. .03 N.S. -.30 N.S. 
ANT SAD Bias  -.19 N.S. -.42 .09* -.46 .06* 
ANT SAD Bias/SA  .41 N.S. .20 N.S. .20 N.S. 
ANT MS2D cognitive control  -.12 N.S. .20 N.S. .14 N.S. 
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Totalscore DEX-K   .14  N.S. .06  N.S. -.21  N.S. 
Behaviour Regulation index  .22  N.S. -.12  N.S. -.07  N.S. 
Metacognition index  .10  N.S. -.28  N.S. -.47  .06* 
BRIEF total  .10  N.S. -.21  N.S. -.37  N.S. 
SRS Social Awareness   .00  N.S. .19  N.S. -.01  N.S. 
SRS Social Cognition   -.07  N.S. .10  N.S. -.07  N.S. 
SRS social Communication  .12  N.S. .09  N.S. -.09  N.S. 
SRS Social Motivation   .34  N.S. .26  N.S. .11  N.S. 
SRS Autistic Mannerisms   .19  N.S. -.19  N.S. -.38  N.S. 
SRS Total  .14  N.S. .09  N.S. -.12  N.S. 
SSRS Cooperation   -.26  N.S. .15  N.S. .23  N.S. 
SSRS Assertion   -.60  .01** -.13  N.S. .00  N.S. 
SSRS Responsibility   -.13  N.S. -.05  N.S. .03  N.S. 
SSRS Self-Control   -.38  N.S. .16  N.S. .21  N.S. 
SSRS Total  -.40  N.S. .06  N.S. .16  N.S. 
CBCL Anxious Depressed  .16  N.S. .16  N.S. .18  N.S. 
CBCL Withdrawn Depressed  .10  N.S. -.29  N.S. -.37  N.S. 
CBCL Somatic Complaints  .02  N.S. .11  N.S. .15  N.S. 
CBCL Social Problems  .21  N.S. -.16  N.S. -.10  N.S. 
CBCL Thought Problems  -.14  N.S. -.38  N.S. -.44  .07* 
CBCL Attention Problems  -.03  N.S. .02  N.S. -.16  N.S. 
CBCL Rule-breaking Behaviour  -.32  N.S. -.06  N.S. -.21  N.S. 
CBCL aggressive Behaviour  .16  N.S. -.10  N.S. -.19  N.S. 
CBCL Other  -.18  N.S. -.15  N.S. -.12  N.S. 
CBCL Internalizing Problems  .13  N.S. -.02  N.S. -.04  N.S. 
CBCL Externalizing Problems  .05  N.S. -.10  N.S. -.21  N.S. 
CBCL Total Problems  .04  N.S. -.14  N.S. -.20  N.S. 
CBCL Affective Problems  .02  N.S. -.22  N.S. -.21  N.S. 
CBCL Anxiety Problems  -.15  N.S. .39  N.S. .24  N.S. 
CBCL  Somatic Problems  -.29  N.S. .19  N.S. .05  N.S. 
CBCL Attention Deficit/Hyperactivity 
Problems  -.05  N.S. .04  N.S. .03  N.S. 
CBCL Oppositional Defiant Problems  .28  N.S. -.02  N.S. -.03  N.S. 
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CBCL Conduct Problems  -.23  N.S. -.10  N.S. -.32  N.S. 
**. Correlation is significant at the 0.05 level (2-tailed). 
*. Correlation is significant at the 0.10 level (2-tailed). 
N.S. = Non-Significant. 
 
     
 
The appearance factor is negatively related to IFE sad, the ability to recognize sad facial 
expressions is weaker when more symptoms affecting the appearance are present. The 
appearance factor is also negatively related to the Assertion scale of the SSRS, indicating that 
more visible symptoms are related to less assertive behaviour. The neurological component is 
negatively related to the score on the task Comprehension of the WISC and the SAD bias 
measure at the 0.10 level, indicating that more neurological symptoms are related to a weaker 
ability to apply knowledge in an adaptive manner, and a lower bias score, indicating less 
impulsive errors. The neurological component is positively related to the task Symbol Search 
at the 0.05 level, children with more neurological symptoms have higher scores on a task for 
processing speed. All other correlations are non-significant. Correlations with the full NF1 
severity scale are comparable: children with higher full-scale scores have higher scores on the 
Symbol Search task. The score on the IFE surprise and shame task are negatively related to 
the full severity scale, indicating that a higher total number of symptoms was related to a 
more errors in recognizing surprised and ashamed facial expressions. SAD bias was also 
negatively related to the total severity scale, more NF1 symptoms were related to less 
impulsive errors on the SAD task. A negative relationship at the 0.10 significance level was 
found between the total number of symptoms and the Meta-cognition index of the BRIEF, 
indicating that children with more NF1 symptoms have lower scores on the Meta-cognition 
index. Also, a negative relationship was found between the total scale score and thought 
problems as measured by the CBCL (α<0.10), children with more NF1 symptoms often had 
less thought problems. 
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Discussion 
The current study has investigated the validity of NF1 severity scales with the use of a newly 
constructed severity scale, and has investigated relationships between this NF1 severity scale 
and cognitive and behavioural outcomes. The first hypothesis, that a two-factor structure 
would be found in the NF1 severity scale, has been confirmed. Symptoms of NF1 can be 
divided into neurological symptoms, affecting the brain and nervous system, and symptoms 
which affect the appearance, mostly cutaneous symptoms. The variability in the symptoms of 
NF1 is large, and to date no comprehensive theory to explain the occurrence of a certain 
combination of symptoms in individuals has been given. Viskochil (2002) gives a thorough 
explanation of the genetics involved in variable expressivity, stating that multiple genetic 
mechanisms can lead to random somatic mutations. Following his argument on variable 
expressivity, it appears that no underlying mechanism for the co-occurrence of symptoms can 
be given, since random gene mutations can lead to random outcomes. However, considering 
the fact that neurological symptoms and symptoms in appearance do seem to co-occur 
respectively, separate underlying mechanisms cannot be excluded and should be studied more 
specifically. 
When including behavioural symptoms in the component structure, it was found that 
ADHD was related to neurological symptoms, indicating that these often co-occur, as was 
hypothesized based on the results of Rowbotham et al. (2009). However, no relationship was 
found between the neurological component and behavioural measures of ADHD, for example 
a high score on the Attention Problems scale of the CBCL. Although associated with ADHD, 
cognitive control was not related to the neurological component. The number of impulsive 
errors made in the sustained attention task was negatively related to the neurological 
component and the total NF1 symptoms, indicating that more neurological symptoms and 
more NF1 symptoms were related to less impulsive errors. Since these results are mixed, they 
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should be interpreted with caution and have to be investigated more thoroughly in future 
studies. Osseous lesions and fine motor skills were negatively related to the neurological 
component. Fine motor impairments may results from osseous lesions, which in turn will 
have their basis in the skeletal system, and will therefore not be strongly related to 
neurological symptoms. Whether or not NF1 is experienced as a burden by the child is 
associated with neurological symptoms. Sebold and colleagues (2004) previously showed that 
adolescents have a more negative severity perception when they experience more cognitive 
problems. Since ADHD and learning problems are related to neurological symptoms, the 
present results are in line with the results of Sebold et al. (2004), children with more 
neurological symptoms, ADHD and/or learning problems more often experience their NF1 as 
a burden in everyday life. ASD was related to symptoms in the appearance, which stands in 
contrast to the hypothesis that ASD would be related to neurological symptoms, since ASD is 
theorized to have a basis in the brain. However, only two children with a diagnosis of ASD 
participated in the study, of which one had a comorbid diagnosis of ADHD. It seems plausible 
that the data concerning ASD are not a reliable reflection of the population of children with 
NF1 and ASD. Speech problems were negatively related to symptoms in appearance, 
indicating that speech problems probably have another origin than visible symptoms. 
Inspection of the data showed that multiple parents stated that their children had weak motor 
skills in the mouth area. Possibly the speech problems are more strongly related to problems 
with their origin in the skeletomuscular system. Having a family member with NF1 was most 
strongly related to symptoms in the appearance. In this study, children with a family member 
with NF1 more often had cutaneous and physical symptoms. 
The second hypothesis, that the NF1 severity scale as well as the separate components 
would be related to outcome measures has been partially confirmed. A number of significant 
relationships were found, the NF1 children with more symptoms in their appearance showed 
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significantly less assertive behaviour and a weaker ability to recognize sad facial expressions. 
It can be theorized that children with many visible symptoms may be more self-conscious, 
and might therefore be less assertive in social interactions; they wait for the initiative of the 
other, which will inform them that the other accepts them. Possibly, children with more 
visible symptoms have experienced negative reactions to their assertive behaviours due to 
their appearance, therefore conditioning them to show less assertive behaviour. A weaker 
ability to recognize sad facial expressions cannot be theoretically explained. Possibly, this 
relationship is a result of specific participant characteristics. It might also be a result of test 
characteristics, multiple children found especially one person’s facial expression hard to 
identify in the ‘sad’ condition of the task which might bias the results. Neurological 
symptoms are negatively related to the task Comprehension, which asks of the participant to 
use their knowledge adaptively and to express their knowledge in words, which is part of 
intelligence. A poor performance on the task Comprehension is often seen in children with 
ASD, since the task requires one to flexibly and adaptively use ones knowledge in social 
situations. The relationship between neurological symptoms and cognitive functioning 
confirms the hypothesis that cognitive functioning is related to impairment on brain-level. A 
significant positive relationship was found between neurological symptoms and overall 
symptoms and processing speed, indicating that children with more neurological symptoms 
and overall more symptoms of NF1 had a faster processing speed. The task Symbol Search is 
a highly structured task, and for example children with ASD do this task relatively well due to 
the structure offered by the task. Possibly, the mechanisms which lead to a poor performance 
on the task Comprehension, e.g. inflexibility, difficulty to adapt knowledge to a social 
situation, is what makes these children good in the Symbol Search task. In line with these 
results, elevated autistic traits were observed in the participating children, as indicated by an 
above average score on the SRS. Total number of symptoms was also related to the 
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Metacognition index of the BRIEF, indicating that children with more NF1 symptoms have 
more trouble self-managing tasks, monitoring ones performance and to actively solve 
problems, which are related to executive functioning, which is often impaired in children with 
ASD and ADHD. Overall NF1 symptoms are related to a weaker ability to recognize 
surprised and ashamed facial expressions. The recognition of more complex facial 
expressions is often impaired in children with ASD. These results are in support of previous 
results by Huijbregts and De Sonneville (2011) who found more autistic traits in their sample 
of NF1 children. The total number of symptoms was negatively related to thought problems. 
Thought problems aren’t a known behavioural problem in children with NF1 and the negative 
relationship may be the result of specific sample characteristics. The remaining relations 
between neurological functioning and cognitive functioning were non-significant. Concluding 
from these results it is possible that children with NF1 share a neuropsychological profile 
commonly seen in children with ASD, which might be related to neurological symptoms.  
Although these results are promising, they have to be seen in the light of their 
limitations. The number of participants is small for the analyses that have been executed, 
rendering the results less reliable. However, in studies involving genetic syndromes small 
samples are common. When converting the prevalence numbers to the Dutch situation, only 
approximately 5000 people with NF1 live in The Netherlands, of which only a small part falls 
in the right age group. Due to recruitment through the Dutch Neurofibromatosis Association, 
only the families who were a member were contacted, decreasing the number of eligible 
participants. All in all, the sample of the current study is of reasonable size when considering 
the limitations of studies involving genetic syndromes. Due to the small sample size relative 
to the analyses that were done, the reliability of the results is reduced. Possibly, when 
reanalyzing the data using a bigger sample, or re-analyzing meta-analytically, results will be 
different, and a more clear picture of the component structure and its relationship to outcome 
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measures can be found. It is possible a third component referring to skeletomuscular 
symptoms would be found, since symptoms related to this system now correlate negatively 
with the found components. Also, the symptom macrocephaly was now negatively related to 
both components, it was shown that this group of participants showed a different pattern of 
symptoms than participants without macrocephaly. The results of Steen et al. (2001) would 
suggest a relationship between neurological symptoms and macrocephaly, since in their study 
UBOs and macrocephaly were related. However, this could not be confirmed in the present 
study. More thorough research with more participants can give clarity about the impact of 
macrocephaly on NF1 symptoms. A second limitation is the fact that a newly constructed NF1 
severity scale was used, which has not been tested for its’ psychometric properties. No 
reliability or validity data have been collected, therefore, the questionnaire might not have 
measured the NF1 severity accurately. However, since the scale was based on existing scales, 
it does have face validity. Some of the symptoms which were listed in the scale were not 
present in any of the participants. It is possible that the scale lists symptoms which do not 
often occur in children with NF1, however, the small variance in the symptoms may also be a 
result of the small sample of the study. Some symptoms are rarer and may not have been 
present in the current sample.  
Although the results have to be interpreted with caution, they showed only three 
significant relationships between the NF1 severity scale and cognitive and behavioural 
outcomes. It appears that severity as measured by a list of present symptoms is not strongly 
related to outcomes in daily life. Possibly, NF1 symptoms should be inspected for underlying 
mechanisms, which in turn cause cognitive and behavioural impairments. It might be possible 
that certain symptoms are related to a cognitive profile which is often seen in children with an 
ASD, as was suggested previously. A way to study mechanisms which are related to physical 
symptoms is to use brain imaging techniques. The current study was part of a brain imaging 
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study which assesses brain functioning while doing cognitive tasks using fMRI. Future results 
may show a clearer picture of the involvement of brain-level deviations in children with NF1 
and cognitive and behavioural outcomes. 
The current study has added to the knowledge on NF1 and what factors may account 
for the mild to severe cognitive and behavioural impairments children with NF1 often face. 
The results indicate that the presence of ASD or cognitive impairments associated with ASD 
might be present in children with NF1. It is important to have a clear picture of the specific 
problems children with NF1 face, in order to give them the best treatment and counselling. 
For clinicians as well as parents it is important to know the impairments of their child, and 
treat the child accordingly. Further, no strong relationships were found between NF1 severity 
as measured with a questionnaire and cognitive and behavioural outcomes. The importance of 
studies to investigate the cause for cognitive and behavioural problems of children with NF1 
must be emphasized, because only when the cause is known, effective treatments can be 
established, for example through medication. Future studies should therefore aim to establish 
a clear cognitive profile of children with NF1, and to relate these to underlying mechanisms 
and behavioural outcomes.  
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Questionnaire characteristics Neurofibromatosis Type I (NF1) 
 
In this questionnaire you will find questions regarding the different characteristics of NF1 which 
could be present in your child. Would you please try to answer as thorough and elaborate as 
possible? All information is important to create an accurate picture of the possible problems your 
child may face. The answers will be treated anonymous and confidential. If you don’t know the 
answer to a question, would you please verify with the child’s treating physician(s)? At the questions 
with a yes or no answer you may simply strike through the answer which is not applicable. 
 
1) Does your child have café-au-lait spots?     Yes/No 
 If yes, could you indicate how many café-au-lait spots your child  
(approximately) has?       ………….. 
2) Does your child have neurofibromas?      Yes/No 
 If yes, could you indicate how many  neurofibromas your child  
(approximately) has?       ………….. 
 Are the neurofibromas on the skin?     ………….. 
 Are the neurofibromas plexiform (tangle formation)?   ………….. 
3) Does your child have freckling in the armpit?    Yes/No 
 Does your child have freckling in the groin?    Yes/No 
4) Does your child have an optic glioma (optic nerve tumour)?  Yes/No 
 Does your child experience problems with sight? 
 …………………………………………………………………………………………………………………………… 
5) Does your child have lisch nodules on the eye?    Yes/No 
6) Does your child have bone abnormalities? You can think of thin and/or  
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long bones or bones not being able to grow back together.  
…………………………………………………………………………………………………………………………… 
7) Is there a family member with Neurofibromatosis type 1 (NF1)? Yes/No 
 If yes, could you indicate which family member?      
…………………………………………………………………………………………………………………………… 
8) Does your child have macrocephaly (large head)?   Yes/No 
 If yes, did your child receive treatment for this?   Yes/No 
9) Does your child have deviations of the spinal column?   Yes/No 
 If yes, could you indicate what kind of deviations? 
 ……………………………………………………………………………………………………………………………. 
 Has your child received treatment for the spinal deviations?  Yes/No 
10) Are the characteristics of NF1 in your child visible to the  
outside world in daily life?      Yes/No 
11) Does your child experience this as a burden?    Yes/No 
 If yes, could you indicate how this expresses itself? 
 ……………………………………………………………………………………………………………………………. 
12) Does your child have hypertension (high blood pressure)?  Yes/No 
 If yes, does your child use medication for this?    Yes/No 
 If yes, which medication is this?     …………….. 
13) Does your child experience a lot of headache?    Yes/No 
 If yes, has there been pointed to a possible cause of the headache? Yes/No  
Could you indicate what cause(s) have been brought forward? 
………………………………………………………………………………………………………………………….. 
Neurological and Appearance-related symptoms in children with Neurofibromatosis type 1 (NF1): The relationship between 
NF1 severity and cognitive and behavioural outcomes 
  58 
Does your child use medication for headache?    Yes/No 
 If yes, which medication is this?     …………… 
14) Does your child have (a) malignant tumour(s)?    Yes/No 
If yes, how is your child treated for this (these) tumour(s)? 
 …………………………………………………………………………………………………………………………… 
 Could you indicate where the tumour(s) is (are) located? 
 …………………………………………………………………………………………………………………………… 
15) Does your child have (a) benign tumour(s)?    Yes/No 
If yes, how is your child treated for this (these) tumour(s)?
 …………………………………………………………………………………………………………………………… 
 Could you indicate where the tumour(s) is (are) located? 
 …………………………………………………………………………………………………………………………… 
16) Does your child experience itch?     Yes/No 
 If yes, does your child use medication for this?    Yes/No 
 If yes, which medication is this?     …………… 
17) Have hormonal problems been identified in your child?   Yes/No 
 If yes, which hormonal problems are this?  
 …………………………………………………………………………………………………………………………… 
 Does your child use medication for hormonal problems?  Yes/No 
 If yes, which medication is this?     ………….. 
18) Have Unidentified Bright Objects been identified in your child?   Yes/No 
 If yes, could you indicate how many UBOs have been identified? ……………. 
19) Have speech problems been identified in your child?   Yes/No 
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 If yes, which speech problems are these? 
 ……………………………………………………………………………………………………………………………. 
Is/was your child treated for speech problems?    Yes/No  
Does your child experience other speech problems? 
 …………………………………………………………………………………………………………………………… 
20) Does your child have gross motor problems  
(e.g. walking and swimming)?       Yes/No 
 If yes, which problems with gross motor skills are these?  
 …………………………………………………………………………………………………………………………….. 
 Is/was your child treated for gross motor problems?   Yes/No 
21) Does your child have fine motor problems?    Yes/No 
 If yes, which problems with fine motor skills are these?  
 …………………………………………………………………………………………………………………………….. 
 Is/was your child treated for fine motor problems?   Yes/No 
22) Has epilepsy been identified in your child?    Yes/No 
 If yes, does your child use medication for this?    Yes/No 
 If yes, which medication is this?     …………… 
23) Have Learning problems been identified in your child?   Yes/No 
 If yes, how do these problems express themselves? 
 ……………………………………………………………………………………………………………………………. 
Has there ever been investigated what might be underlying  
the learning problems? (e.g. problems with memory, interpretation,  
problem solving skills)? 
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……………………………………………………………………………………………………………………………..  
Has your child received treatment for learning problems?  Yes/No 
24) Have psychological problems been identified in your child?  Yes/No 
 If yes, which problems are these?  
 ……………………………………………………………………………………………………………………………. 
 Has your child received treatment for psychological problems?  Yes/No 
 Does your child use medication for psychological problems?  Yes/No 
 If yes, which medication is this?     …………… 
In your opinion, does your child experience psychological problems? Yes/No 
If yes, which psychological problems are these? 
 …………………………………………………………………………………………………………………………… 
25) Has ADHD been identified in your child?    Yes/No 
 Is yes, does your child use medication for this?    Yes/No 
 If yes, which medication is this?     …………… 
 In your opinion, does your child show ADHD-related behaviours? Yes/No 
 If yes, which ADHD related behaviours are this? 
 ………………………………………………………………………………………………………………………….. 
26) Has there been identified an Autistic Spectrum Disorder (ASD)  
in your child? (e.g. autism, Asperger syndrome, PDD-NOS)    Yes/No 
If yes, which ASD is this?      …………… 
Does your child use medication for an ASD?    Yes/No 
If yes, which medication is this?     …………… 
In your opinion, does your child show autistic traits?   Yes/No 
Neurological and Appearance-related symptoms in children with Neurofibromatosis type 1 (NF1): The relationship between 
NF1 severity and cognitive and behavioural outcomes 
  61 
If yes, which autistic traits are these? 
……………………………………………………………………………………………………………………………. 
27) Has there been identified a behaviour disorder in your child?  Yes/No 
 If yes, which behaviour disorder is this?     …………… 
 Does your child use medication for a behaviour disorder?  Yes/No 
 If yes, which medication is this?     …………… 
 In your opinion, does your child experience behaviour problems? Yes/No 
 If yes, which behaviour problems are these? 
 ……………………………………………………………………………………………………………………………… 
28) Does your child have social problems?     Yes/No 
 If yes, which social problems does your child have?    Yes/No 
 Is your child treated for social problems?    Yes/No 
29) Does your child experience other specific behaviours or problems? 
 ………………………………………………………………………………………………………………………………  
 ……………………………………………………………………………………………………………………………… 
 
Finally, a few questions about the treatment of your child and persons with whom your child has 
been in contact. 
 
30)  Who is the treating physician or treating team of your child (name(s) and hospital)? 
………………………………………………………………………………………………………………………………. 
………………………………………………………………………………………………………………………………. 
31)  Who is the general practitioner of your child (name and place)? 
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 ………………………………………………………………………………………………………………………………. 
 ………………………………………………………………………………………………………………………………. 
32) What is the precise treatment history of your child from the moment the NF1 was identified 
up till now? 
 ………………………………………………………………………………………………………………………………. 
 ………………………………………………………………………………………………………………………………. 
 ………………………………………………………………………………………………………………………………. 
 ………………………………………………………………………………………………………………………………. 
Thank you very much for filling in this questionnaire. If there are any questions which you cannot 
answer at the moment, but maybe after consulting your doctor you can, please let this know the 
researcher who brings back your child. 
 
 
